Stella Pharma Corporation (TYO:4888)
Japan · Delayed Price · Currency is JPY 316.00
-5.00 (-1.56%)
Jun 24, 2026, 2:08 PM JST
Stella Pharma Revenue
In the fiscal year ending March 31, 2026, Stella Pharma had annual revenue of 323.00M JPY, down -66.39%. Stella Pharma had revenue of 62.00M in the quarter ending March 31, 2026, a decrease of -91.23%.
Revenue
323.00M
Revenue Growth
-66.39%
P/S Ratio
34.82
Revenue / Employee
7.51M
Employees
43
Market Cap
11.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 323.00M | -638.00M | -66.39% |
| Mar 31, 2025 | 961.00M | 692.00M | 257.25% |
| Mar 31, 2024 | 269.00M | 40.00M | 17.47% |
| Mar 31, 2023 | 229.00M | 129.00M | 129.00% |
| Mar 31, 2022 | 100.00M | -105.00M | -51.22% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.82B |
| StemCell Institute | 2.81B |
| ReproCELL | 2.23B |
| Immuno-Biological Laboratories | 1.00B |
| OncoTherapy Science | 808.00M |
| Nano Holdings | 174.00M |
| CellSeed | 161.00M |
| ADR120S | 50.00M |